Literature DB >> 24551269

Requirement for TLR2 in the development of albuminuria, inflammation and fibrosis in experimental diabetic nephropathy.

Jin Ma1, Huiling Wu2, Cathy Y Zhao1, Usha Panchapakesan3, Carol Pollock3, Steven J Chadban2.   

Abstract

Inflammation and fibrosis are essential elements of diabetic nephropathy (DN). We tested the hypothesis that these elements are dependent upon Toll-like receptor 2 (TLR2) signalling by examining WT and TLR2(-/-) mice in an experimental model of DN. Diabetes was induced in WT and TLR2(-/-) mice by i.p. injection of streptozotocin. Kidney injury was assessed at 6, 12 and 24 weeks after induction of diabetes. Gene expression of TLR2, its endogenous ligands and downstream cytokines, chemokines and fibrogenic molecules were upregulated in kidneys from WT mice with streptozotocin diabetes. TLR2(-/-) mice were protected against the development of DN, exhibiting less albuminuria, inflammation, glomerular hypertrophy and hypercellularity, podocyte and tubular injury as compared to diabetic WT controls. Marked reductions in interstitial collagen deposition, myofibroblast activation (α-SMA) and expression of fibrogenic genes (TGF-β and fibronectin) were also evident in TLR2 deficient mice. Consistent with our in vivo results, high glucose directly promoted TLR2 activation in podocytes and tubular epithelial cells (TECs) in vitro, resulting in NF-κB activation, inflammation and TGF-β production. We conclude that TLR2 was required for the full development of inflammation, kidney damage and fibrosis in this model of DN. As TLR2 is known to be expressed by intrinsic kidney cells and as high concentration glucose stimulated podocytes and TECs in vitro to express TLR2 and TLR2 ligands, pro-inflammatory and pro-fibrotic cytokines in a TLR2 dependent manner in the present study, it appears likely that TLR2 signalling in intrinsic kidney cells contributes to the pathogenesis of diabetic nephropathy.

Entities:  

Keywords:  Diabetic nephropathy; Toll like receptor 2; fibrosis; podocytes

Mesh:

Substances:

Year:  2014        PMID: 24551269      PMCID: PMC3925893     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  54 in total

1.  HMGB1 signals through toll-like receptor (TLR) 4 and TLR2.

Authors:  Man Yu; Haichao Wang; Aihao Ding; Douglas T Golenbock; Eicke Latz; Christopher J Czura; Matthew J Fenton; Kevin J Tracey; Huan Yang
Journal:  Shock       Date:  2006-08       Impact factor: 3.454

2.  TLR4 enhances TGF-beta signaling and hepatic fibrosis.

Authors:  Ekihiro Seki; Samuele De Minicis; Christoph H Osterreicher; Johannes Kluwe; Yosuke Osawa; David A Brenner; Robert F Schwabe
Journal:  Nat Med       Date:  2007-10-21       Impact factor: 53.440

3.  Increased toll-like receptor (TLR) 2 and TLR4 expression in monocytes from patients with type 1 diabetes: further evidence of a proinflammatory state.

Authors:  Sridevi Devaraj; Mohan R Dasu; Jason Rockwood; William Winter; Steven C Griffen; Ishwarlal Jialal
Journal:  J Clin Endocrinol Metab       Date:  2007-11-20       Impact factor: 5.958

4.  Toll-like receptor 4 mediates maladaptive left ventricular remodeling and impairs cardiac function after myocardial infarction.

Authors:  Leo Timmers; Joost P G Sluijter; J Karlijn van Keulen; Imo E Hoefer; Marcel G J Nederhoff; Marie-Jose Goumans; Pieter A Doevendans; Cees J A van Echteld; Jaap A Joles; Paul H Quax; Jan J Piek; Gerard Pasterkamp; Dominique P V de Kleijn
Journal:  Circ Res       Date:  2007-11-15       Impact factor: 17.367

5.  TLR4 activation mediates kidney ischemia/reperfusion injury.

Authors:  Huiling Wu; Gang Chen; Kate R Wyburn; Jianlin Yin; Patrick Bertolino; Josette M Eris; Stephen I Alexander; Alexandra F Sharland; Steven J Chadban
Journal:  J Clin Invest       Date:  2007-10       Impact factor: 14.808

6.  Antibody blockade of c-fms suppresses the progression of inflammation and injury in early diabetic nephropathy in obese db/db mice.

Authors:  A K H Lim; F Y Ma; D J Nikolic-Paterson; M C Thomas; L A Hurst; G H Tesch
Journal:  Diabetologia       Date:  2009-05-23       Impact factor: 10.122

7.  TLR4 signaling mediates inflammation and tissue injury in nephrotoxicity.

Authors:  Binzhi Zhang; Ganesan Ramesh; Satoshi Uematsu; Shizuo Akira; W Brian Reeves
Journal:  J Am Soc Nephrol       Date:  2008-02-06       Impact factor: 10.121

8.  TLR4 links podocytes with the innate immune system to mediate glomerular injury.

Authors:  Miriam C Banas; Bernhard Banas; Kelly L Hudkins; Tomasz A Wietecha; Masayuki Iyoda; Elisabeth Bock; Peter Hauser; Jeffrey W Pippin; Stuart J Shankland; Kelly D Smith; Benjamin Stoelcker; Gang Liu; Hermann-Josef Gröne; Bernhard K Krämer; Charles E Alpers
Journal:  J Am Soc Nephrol       Date:  2008-02-06       Impact factor: 10.121

9.  Podocyte detachment and reduced glomerular capillary endothelial fenestration promote kidney disease in type 2 diabetic nephropathy.

Authors:  E Jennifer Weil; Kevin V Lemley; Clinton C Mason; Berne Yee; Lois I Jones; Kristina Blouch; Tracy Lovato; Meghan Richardson; Bryan D Myers; Robert G Nelson
Journal:  Kidney Int       Date:  2012-06-20       Impact factor: 10.612

10.  Increased levels of ligands of Toll-like receptors 2 and 4 in type 1 diabetes.

Authors:  S Devaraj; M R Dasu; S H Park; I Jialal
Journal:  Diabetologia       Date:  2009-05-20       Impact factor: 10.122

View more
  16 in total

1.  Dietary Fiber Protects against Diabetic Nephropathy through Short-Chain Fatty Acid-Mediated Activation of G Protein-Coupled Receptors GPR43 and GPR109A.

Authors:  Yan Jun Li; Xiaochen Chen; Tony K Kwan; Yik Wen Loh; Julian Singer; Yunzi Liu; Jin Ma; Jian Tan; Laurence Macia; Charles R Mackay; Steven J Chadban; Huiling Wu
Journal:  J Am Soc Nephrol       Date:  2020-05-01       Impact factor: 10.121

2.  Schisandrin C attenuates renal damage in diabetic nephropathy by regulating macrophage polarization.

Authors:  Yu Wang; Jingqiu Cui; Ming Liu; Yingqi Shao; Xiaoying Dong
Journal:  Am J Transl Res       Date:  2021-01-15       Impact factor: 4.060

3.  TLR2 knockout protects against diabetes-mediated changes in cerebral perfusion and cognitive deficits.

Authors:  Trevor Hardigan; Caterina Hernandez; Rebecca Ward; M Nasrul Hoda; Adviye Ergul
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2017-02-22       Impact factor: 3.619

4.  Linagliptin reduces effects of ET-1 and TLR2-mediated cerebrovascular hyperreactivity in diabetes.

Authors:  Trevor Hardigan; Yasir Abdul; Adviye Ergul
Journal:  Life Sci       Date:  2016-02-17       Impact factor: 5.037

Review 5.  Insights into the Mechanisms Involved in the Expression and Regulation of Extracellular Matrix Proteins in Diabetic Nephropathy.

Authors:  C Hu; L Sun; L Xiao; Y Han; X Fu; X Xiong; X Xu; Y Liu; S Yang; F Liu; Y S Kanwar
Journal:  Curr Med Chem       Date:  2015       Impact factor: 4.530

Review 6.  Inflammation in obesity, diabetes, and related disorders.

Authors:  Theresa V Rohm; Daniel T Meier; Jerrold M Olefsky; Marc Y Donath
Journal:  Immunity       Date:  2022-01-11       Impact factor: 31.745

7.  Hyperglycemia induces Toll-like receptor-2 and -4 expression and activity in human microvascular retinal endothelial cells: implications for diabetic retinopathy.

Authors:  Uthra Rajamani; Ishwarlal Jialal
Journal:  J Diabetes Res       Date:  2014-12-31       Impact factor: 4.011

8.  CYLD Deubiquitinase Negatively Regulates High Glucose-Induced NF-κB Inflammatory Signaling in Mesangial Cells.

Authors:  Yanhui Li; Wei Huang; Youhua Xu; Luping Zhou; Yaling Liang; Chenlin Gao; Yang Long; Yong Xu
Journal:  Biomed Res Int       Date:  2017-11-12       Impact factor: 3.411

Review 9.  Innate immunity in diabetic kidney disease.

Authors:  Sydney C W Tang; Wai Han Yiu
Journal:  Nat Rev Nephrol       Date:  2020-01-15       Impact factor: 28.314

10.  Elevation of Non-Classical (CD14+/lowCD16++) Monocytes Is Associated with Increased Albuminuria and Urine TGF-β1 in HIV-Infected Individuals on Stable Antiretroviral Therapy.

Authors:  Brooks I Mitchell; Mary Margaret Byron; Roland C Ng; Dominic C Chow; Lishomwa C Ndhlovu; Cecilia M Shikuma
Journal:  PLoS One       Date:  2016-04-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.